# Kymera Therapeutics, Inc.: overview

KYMR · Nasdaq · CIK 1815442 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kymr.md) · [Financials](/companies/kymr/financials.md) · [Filings](/companies/kymr/filings.md) · [Insiders](/companies/kymr/insiders.md)

Latest reported revenue: [$65.0m](/filings/0001193125-26-333849.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-333849).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.7](/filings/0001193125-25-263550.md) | [7.4 d](/filings/0001193125-26-073395.md) | [22.1](/filings/0001193125-26-193967.md) | [11.5](/filings/0001193125-26-333849.md) | [2.8](/filings/0001193125-25-263550.md) | [2.9 d](/filings/0001193125-26-073395.md) | [34.4](/filings/0001193125-26-193967.md) | [65.0](/filings/0001193125-26-333849.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(1927.9%)](/filings/0001193125-25-263550.md) | [(1092.2%) d](/filings/0001193125-26-073395.md) | [(336.8%)](/filings/0001193125-26-193967.md) | [(736.8%)](/filings/0001193125-26-333849.md) | [(3347.4%)](/filings/0001193125-25-263550.md) | [(3411.0%) d](/filings/0001193125-26-073395.md) | [(244.9%)](/filings/0001193125-26-193967.md) | [(116.3%)](/filings/0001193125-26-333849.md) |
| Net margin | % | [(1670.3%)](/filings/0001193125-25-263550.md) | [(956.9%) d](/filings/0001193125-26-073395.md) | [(296.7%)](/filings/0001193125-26-193967.md) | [(667.6%)](/filings/0001193125-26-333849.md) | [(2973.0%)](/filings/0001193125-25-263550.md) | [(3030.7%) d](/filings/0001193125-26-073395.md) | [(201.5%)](/filings/0001193125-26-193967.md) | [(94.2%)](/filings/0001193125-26-333849.md) |
| Diluted EPS | $ per share | [(0.82)](/filings/0001193125-25-263550.md) | not reported | [(0.82)](/filings/0001193125-26-193967.md) | [(0.95)](/filings/0001193125-26-333849.md) | [(0.94)](/filings/0001193125-25-263550.md) | not reported | [(0.71)](/filings/0001193125-26-193967.md) | [(0.62)](/filings/0001193125-26-333849.md) |
| Free cash flow | $m | [(50.4) d](/filings/0001193125-25-263550.md) | [(62.7) d](/filings/0001193125-26-073395.md) | [(79.6)](/filings/0001193125-26-193967.md) | [(60.6) d](/filings/0001193125-26-333849.md) | [(27.3) d](/filings/0001193125-25-263550.md) | [(66.9) d](/filings/0001193125-26-073395.md) | [(89.3)](/filings/0001193125-26-193967.md) | [(54.5) d](/filings/0001193125-26-333849.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [72.8](/filings/0000950170-24-018414.md) | [46.8](/filings/0000950170-25-028355.md) | [78.6](/filings/0001193125-26-073395.md) | [47.1](/filings/0001193125-26-073395.md) | [39.2](/filings/0001193125-26-073395.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(138.0%)](/filings/0000950170-24-018414.md) | [(344.4%)](/filings/0000950170-25-028355.md) | [(210.6%)](/filings/0001193125-26-073395.md) | [(555.8%)](/filings/0001193125-26-073395.md) | [(891.1%)](/filings/0001193125-26-073395.md) |
| Net margin | % | [(137.6%)](/filings/0000950170-24-018414.md) | [(330.6%)](/filings/0000950170-25-028355.md) | [(187.0%)](/filings/0001193125-26-073395.md) | [(475.6%)](/filings/0001193125-26-073395.md) | [(794.0%)](/filings/0001193125-26-073395.md) |
| Diluted EPS | $ per share | [(2.09)](/filings/0000950170-24-018414.md) | [(2.87)](/filings/0000950170-25-028355.md) | [(2.52)](/filings/0001193125-26-073395.md) | [(2.98)](/filings/0001193125-26-073395.md) | [(3.69)](/filings/0001193125-26-073395.md) |
| Free cash flow | $m | [(131)](/filings/0000950170-24-018414.md) | [(156)](/filings/0000950170-25-028355.md) | [(137)](/filings/0001193125-26-073395.md) | [(207)](/filings/0001193125-26-073395.md) | [(234)](/filings/0001193125-26-073395.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kymr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.42bn | 12,349,256 |  | Added +649,306 |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $992.7m | 8,657,242 |  | Unchanged |
| [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $857.1m | 7,474,747 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $635.1m | 5,538,210 |  | Added +477,334 |
| [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $444.0m | 3,872,052 |  | Reduced −1,630,658 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $421.4m | 3,675,028 |  | Reduced −214,659 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $343.1m | 2,992,193 |  | Added +118,137 |
| [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $336.7m | 2,935,830 |  | Reduced −251,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $336.3m | 2,932,378 |  | Added +52,054 |
| [Atlas Venture Life Science Advisors, LLC](/funds/1917529.md) | 2026-06-30 | $326.5m | 2,847,541 |  | Reduced −1,730,467 |

## Recent filings

[All 640 filings](/companies/kymr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 07:10 ET | [8-K](/filings/0001193125-26-436965.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-436965 |
| 2026-08-05 | 07:15 ET | [10-Q](/filings/0001193125-26-333849.md) | Quarterly report, period 2026-06-30 | 0001193125-26-333849 |
| 2026-08-05 | 07:10 ET | [8-K](/filings/0001193125-26-333834.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-333834 |
| 2026-07-27 | 16:10 ET | [8-K](/filings/0001193125-26-318078.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-318078 |
| 2026-06-26 | 18:43 ET | [SCHEDULE 13D/A](/filings/0000921895-26-001687.md) | Ownership report, active investor, amended | 0000921895-26-001687 |
| 2026-06-25 | 07:10 ET | [8-K](/filings/0001193125-26-281817.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-281817 |
| 2026-06-24 | 16:07 ET | [8-K](/filings/0001193125-26-281051.md) | 5.07 Shareholder vote results | 0001193125-26-281051 |
| 2026-06-08 | 16:05 ET | [8-K](/filings/0001193125-26-261698.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-261698 |
| 2026-04-30 | 07:15 ET | [10-Q](/filings/0001193125-26-193967.md) | Quarterly report, period 2026-03-31 | 0001193125-26-193967 |
| 2026-04-30 | 07:10 ET | [8-K](/filings/0001193125-26-193957.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-193957 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-073395.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/7ddf25b2-8b47-46ce-a04b-1e71aed40def)

## About the filer

- CIK: 1815442
- Tickers: KYMR
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 07:17 ET. No prices; not investment advice.